TG Therapeutics, Inc. (NASDAQ: TGTX) Stock Competitors & Peer Comparison
See TGTX's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for TGTX and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| TGTX | $64.51 | -0.08% | 9.8B | 23.37 | $2.76 | N/A |
| VRTX | $538.60 | -0.74% | 136.6B | 28.30 | $19.03 | N/A |
| REGN | $955.47 | +0.45% | 98.8B | 20.94 | $45.63 | +0.38% |
| MRNA | $223.37 | -3.45% | 90.4B | -27.41 | -$8.15 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $960.04 | -2.17% | 60B | 34.62 | $27.73 | N/A |
| ONC | $416.54 | +0.14% | 44.5B | 73.33 | $5.68 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMD | $172.29 | -2.30% | 37.3B | -19.53 | -$8.82 | N/A |
| RVMDW | $7.68 | -5.83% | 35.9B | -0.87 | -$8.82 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
TGTX vs VRTX Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, VRTX has a market cap of 136.6B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while VRTX trades at $538.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas VRTX's P/E ratio is 28.30. In terms of profitability, TGTX's ROE is +0.18%, compared to VRTX's ROE of +0.20%. Regarding short-term risk, TGTX is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
TGTX vs REGN Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, REGN has a market cap of 98.8B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while REGN trades at $955.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas REGN's P/E ratio is 20.94. In terms of profitability, TGTX's ROE is +0.18%, compared to REGN's ROE of +0.15%. Regarding short-term risk, TGTX is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check REGN's competition here
Moderna, Inc. (NASDAQ: MRNA)
TGTX vs MRNA Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, MRNA has a market cap of 90.4B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while MRNA trades at $223.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas MRNA's P/E ratio is -27.41. In terms of profitability, TGTX's ROE is +0.18%, compared to MRNA's ROE of -0.38%. Regarding short-term risk, TGTX is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check MRNA's competition here
Verona Pharma plc (NASDAQ: VRNA)
TGTX vs VRNA Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas VRNA's P/E ratio is -102.80. In terms of profitability, TGTX's ROE is +0.18%, compared to VRNA's ROE of -0.61%. Regarding short-term risk, TGTX is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
TGTX vs ARGX Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, ARGX has a market cap of 60B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while ARGX trades at $960.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas ARGX's P/E ratio is 34.62. In terms of profitability, TGTX's ROE is +0.18%, compared to ARGX's ROE of +0.17%. Regarding short-term risk, TGTX is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check ARGX's competition here
BeOne Medicines AG (NASDAQ: ONC)
TGTX vs ONC Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, ONC has a market cap of 44.5B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while ONC trades at $416.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas ONC's P/E ratio is 73.33. In terms of profitability, TGTX's ROE is +0.18%, compared to ONC's ROE of +0.18%. Regarding short-term risk, TGTX is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check ONC's competition here
Seagen Inc. (NASDAQ: SGEN)
TGTX vs SGEN Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas SGEN's P/E ratio is -57.19. In terms of profitability, TGTX's ROE is +0.18%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, TGTX is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check SGEN's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
TGTX vs RVMD Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, RVMD has a market cap of 37.3B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while RVMD trades at $172.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas RVMD's P/E ratio is -19.53. In terms of profitability, TGTX's ROE is +0.18%, compared to RVMD's ROE of -0.92%. Regarding short-term risk, TGTX is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check RVMD's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
TGTX vs RVMDW Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, RVMDW has a market cap of 35.9B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while RVMDW trades at $7.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas RVMDW's P/E ratio is -0.87. In terms of profitability, TGTX's ROE is +0.18%, compared to RVMDW's ROE of -0.92%. Regarding short-term risk, TGTX is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check RVMDW's competition here
Genmab A/S (NASDAQ: GMAB)
TGTX vs GMAB Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, GMAB has a market cap of 31.7B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while GMAB trades at $51.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas GMAB's P/E ratio is 38.71. In terms of profitability, TGTX's ROE is +0.18%, compared to GMAB's ROE of +0.12%. Regarding short-term risk, TGTX is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check GMAB's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
TGTX vs ROIV Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, ROIV has a market cap of 28.6B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while ROIV trades at $39.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas ROIV's P/E ratio is -37.61. In terms of profitability, TGTX's ROE is +0.18%, compared to ROIV's ROE of -0.08%. Regarding short-term risk, TGTX is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check ROIV's competition here
Insmed Incorporated (NASDAQ: INSM)
TGTX vs INSM Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, INSM has a market cap of 26.6B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while INSM trades at $121.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas INSM's P/E ratio is -42.96. In terms of profitability, TGTX's ROE is +0.18%, compared to INSM's ROE of -0.83%. Regarding short-term risk, TGTX is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check INSM's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
TGTX vs UTHR Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, UTHR has a market cap of 25.2B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while UTHR trades at $591.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas UTHR's P/E ratio is 21.15. In terms of profitability, TGTX's ROE is +0.18%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, TGTX is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check UTHR's competition here
Incyte Corporation (NASDAQ: INCY)
TGTX vs INCY Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, INCY has a market cap of 24.7B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while INCY trades at $120.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas INCY's P/E ratio is 16.26. In terms of profitability, TGTX's ROE is +0.18%, compared to INCY's ROE of +0.07%. Regarding short-term risk, TGTX is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check INCY's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
TGTX vs ALNY Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, ALNY has a market cap of 22.1B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while ALNY trades at $165.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas ALNY's P/E ratio is 8.34. In terms of profitability, TGTX's ROE is +0.18%, compared to ALNY's ROE of +1.60%. Regarding short-term risk, TGTX is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check ALNY's competition here
BioNTech SE (NASDAQ: BNTX)
TGTX vs BNTX Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, BNTX has a market cap of 21.2B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while BNTX trades at $85.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas BNTX's P/E ratio is -11.10. In terms of profitability, TGTX's ROE is +0.18%, compared to BNTX's ROE of -0.08%. Regarding short-term risk, TGTX is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check BNTX's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
TGTX vs BGNE Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas BGNE's P/E ratio is -22.55. In terms of profitability, TGTX's ROE is +0.18%, compared to BGNE's ROE of +0.18%. Regarding short-term risk, TGTX is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
TGTX vs DNA-WT Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, TGTX's ROE is +0.18%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, TGTX is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check DNA-WT's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
TGTX vs ASND Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, ASND has a market cap of 18.1B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while ASND trades at $275.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas ASND's P/E ratio is -113.80. In terms of profitability, TGTX's ROE is +0.18%, compared to ASND's ROE of +1.08%. Regarding short-term risk, TGTX is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check ASND's competition here
Exelixis, Inc. (NASDAQ: EXEL)
TGTX vs EXEL Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, EXEL has a market cap of 17.3B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while EXEL trades at $69.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas EXEL's P/E ratio is 19.71. In terms of profitability, TGTX's ROE is +0.18%, compared to EXEL's ROE of +0.46%. Regarding short-term risk, TGTX is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check EXEL's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
TGTX vs NBIX Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, NBIX has a market cap of 16.9B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while NBIX trades at $167.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas NBIX's P/E ratio is 24.19. In terms of profitability, TGTX's ROE is +0.18%, compared to NBIX's ROE of +0.20%. Regarding short-term risk, TGTX is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
TGTX vs JAZZ Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, JAZZ has a market cap of 15.5B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while JAZZ trades at $241.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas JAZZ's P/E ratio is 9.01. In terms of profitability, TGTX's ROE is +0.18%, compared to JAZZ's ROE of +0.05%. Regarding short-term risk, TGTX is less volatile compared to JAZZ. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
TGTX vs BBIO Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, BBIO has a market cap of 15.3B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while BBIO trades at $78.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas BBIO's P/E ratio is -25.76. In terms of profitability, TGTX's ROE is +0.18%, compared to BBIO's ROE of +0.27%. Regarding short-term risk, TGTX is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check BBIO's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
TGTX vs KRTX Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas KRTX's P/E ratio is -28.09. In terms of profitability, TGTX's ROE is +0.18%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, TGTX is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check KRTX's competition here
Bio-Techne Corporation (NASDAQ: TECH)
TGTX vs TECH Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, TECH has a market cap of 11.4B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while TECH trades at $72.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas TECH's P/E ratio is 37.53. In terms of profitability, TGTX's ROE is +0.18%, compared to TECH's ROE of +0.08%. Regarding short-term risk, TGTX is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check TECH's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
TGTX vs HALO Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, HALO has a market cap of 11.4B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while HALO trades at $100.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas HALO's P/E ratio is 18.71. In terms of profitability, TGTX's ROE is +0.18%, compared to HALO's ROE of +5.44%. Regarding short-term risk, TGTX is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check HALO's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
TGTX vs SMMT Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, SMMT has a market cap of 11.3B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while SMMT trades at $14.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas SMMT's P/E ratio is -12.63. In terms of profitability, TGTX's ROE is +0.18%, compared to SMMT's ROE of -1.39%. Regarding short-term risk, TGTX is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check SMMT's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
TGTX vs RNAM Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas RNAM's P/E ratio is -17.39. In terms of profitability, TGTX's ROE is +0.18%, compared to RNAM's ROE of -0.36%. Regarding short-term risk, TGTX is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check RNAM's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
TGTX vs BMRN Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, BMRN has a market cap of 11.1B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while BMRN trades at $57.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas BMRN's P/E ratio is 27.51. In terms of profitability, TGTX's ROE is +0.18%, compared to BMRN's ROE of -0.00%. Regarding short-term risk, TGTX is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check BMRN's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
TGTX vs KYMR Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, KYMR has a market cap of 10.9B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while KYMR trades at $127.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas KYMR's P/E ratio is -35.24. In terms of profitability, TGTX's ROE is +0.18%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, TGTX is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check KYMR's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
TGTX vs PCVX Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, PCVX has a market cap of 10B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while PCVX trades at $63.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas PCVX's P/E ratio is -8.31. In terms of profitability, TGTX's ROE is +0.18%, compared to PCVX's ROE of -0.42%. Regarding short-term risk, TGTX is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check PCVX's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
TGTX vs MDGL Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, MDGL has a market cap of 9.9B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while MDGL trades at $427.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas MDGL's P/E ratio is -33.39. In terms of profitability, TGTX's ROE is +0.18%, compared to MDGL's ROE of -0.27%. Regarding short-term risk, TGTX is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check MDGL's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
TGTX vs SYRE Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, SYRE has a market cap of 9.9B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while SYRE trades at $104.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas SYRE's P/E ratio is -53.33. In terms of profitability, TGTX's ROE is +0.18%, compared to SYRE's ROE of -0.30%. Regarding short-term risk, TGTX is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check SYRE's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
TGTX vs RXDX Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas RXDX's P/E ratio is -56.47. In terms of profitability, TGTX's ROE is +0.18%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, TGTX is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check RXDX's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
TGTX vs PRAX Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, PRAX has a market cap of 9.2B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while PRAX trades at $328.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas PRAX's P/E ratio is -25.38. In terms of profitability, TGTX's ROE is +0.18%, compared to PRAX's ROE of -0.29%. Regarding short-term risk, TGTX is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check PRAX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
TGTX vs NUVL Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas NUVL's P/E ratio is -21.79. In terms of profitability, TGTX's ROE is +0.18%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, TGTX is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check NUVL's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
TGTX vs KRYS Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, KRYS has a market cap of 9B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while KRYS trades at $305.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas KRYS's P/E ratio is 38.25. In terms of profitability, TGTX's ROE is +0.18%, compared to KRYS's ROE of +0.17%. Regarding short-term risk, TGTX is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check KRYS's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
TGTX vs CRNX Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas CRNX's P/E ratio is -16.86. In terms of profitability, TGTX's ROE is +0.18%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, TGTX is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check CRNX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
TGTX vs IMGN Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas IMGN's P/E ratio is -111.55. In terms of profitability, TGTX's ROE is +0.18%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, TGTX is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check IMGN's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
TGTX vs PTGX Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, PTGX has a market cap of 8.5B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while PTGX trades at $130.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas PTGX's P/E ratio is 127.14. In terms of profitability, TGTX's ROE is +0.18%, compared to PTGX's ROE of +0.43%. Regarding short-term risk, TGTX is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check PTGX's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
TGTX vs APGE Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas APGE's P/E ratio is -31.19. In terms of profitability, TGTX's ROE is +0.18%, compared to APGE's ROE of -0.30%. Regarding short-term risk, TGTX is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check APGE's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
TGTX vs BPMC Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas BPMC's P/E ratio is -51.58. In terms of profitability, TGTX's ROE is +0.18%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, TGTX is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check BPMC's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
TGTX vs CERE Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas CERE's P/E ratio is -16.47. In terms of profitability, TGTX's ROE is +0.18%, compared to CERE's ROE of -0.72%. Regarding short-term risk, TGTX is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check CERE's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
TGTX vs RYTM Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, RYTM has a market cap of 8B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while RYTM trades at $115.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas RYTM's P/E ratio is -36.98. In terms of profitability, TGTX's ROE is +0.18%, compared to RYTM's ROE of -0.84%. Regarding short-term risk, TGTX is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check RYTM's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
TGTX vs CYTK Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, CYTK has a market cap of 7.8B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while CYTK trades at $56.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas CYTK's P/E ratio is -7.77. In terms of profitability, TGTX's ROE is +0.18%, compared to CYTK's ROE of +1.57%. Regarding short-term risk, TGTX is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check CYTK's competition here
Abivax S.A. (NASDAQ: ABVX)
TGTX vs ABVX Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, ABVX has a market cap of 7.5B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while ABVX trades at $87.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas ABVX's P/E ratio is -14.35. In terms of profitability, TGTX's ROE is +0.18%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, TGTX is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check ABVX's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
TGTX vs AXSM Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, AXSM has a market cap of 7.5B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while AXSM trades at $141.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas AXSM's P/E ratio is -36.99. In terms of profitability, TGTX's ROE is +0.18%, compared to AXSM's ROE of -1.90%. Regarding short-term risk, TGTX is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check AXSM's competition here
Metsera, Inc. (NASDAQ: MTSR)
TGTX vs MTSR Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas MTSR's P/E ratio is -23.58. In terms of profitability, TGTX's ROE is +0.18%, compared to MTSR's ROE of -0.47%. Regarding short-term risk, TGTX is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check MTSR's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
TGTX vs TWST Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, TWST has a market cap of 7.3B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while TWST trades at $111.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas TWST's P/E ratio is -50.27. In terms of profitability, TGTX's ROE is +0.18%, compared to TWST's ROE of -0.23%. Regarding short-term risk, TGTX is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check TWST's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
TGTX vs ORKA Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, ORKA has a market cap of 7.1B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while ORKA trades at $105.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas ORKA's P/E ratio is -54.30. In terms of profitability, TGTX's ROE is +0.18%, compared to ORKA's ROE of -0.19%. Regarding short-term risk, TGTX is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check ORKA's competition here
Immunovant, Inc. (NASDAQ: IMVT)
TGTX vs IMVT Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, IMVT has a market cap of 7.1B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while IMVT trades at $34.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas IMVT's P/E ratio is -12.12. In terms of profitability, TGTX's ROE is +0.18%, compared to IMVT's ROE of -0.63%. Regarding short-term risk, TGTX is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check IMVT's competition here
10x Genomics, Inc. (NASDAQ: TXG)
TGTX vs TXG Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, TXG has a market cap of 7B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while TXG trades at $58.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas TXG's P/E ratio is -98.63. In terms of profitability, TGTX's ROE is +0.18%, compared to TXG's ROE of -0.08%. Regarding short-term risk, TGTX is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check TXG's competition here
Kodiak Sciences Inc. (NASDAQ: KOD)
TGTX vs KOD Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, KOD has a market cap of 7B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while KOD trades at $111.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas KOD's P/E ratio is -26.66. In terms of profitability, TGTX's ROE is +0.18%, compared to KOD's ROE of -2.88%. Regarding short-term risk, TGTX is less volatile compared to KOD. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check KOD's competition here
Merus N.V. (NASDAQ: MRUS)
TGTX vs MRUS Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas MRUS's P/E ratio is -17.05. In terms of profitability, TGTX's ROE is +0.18%, compared to MRUS's ROE of -0.31%. Regarding short-term risk, TGTX is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check MRUS's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
TGTX vs ARWR Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, ARWR has a market cap of 6.7B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while ARWR trades at $47.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas ARWR's P/E ratio is -21.24. In terms of profitability, TGTX's ROE is +0.18%, compared to ARWR's ROE of -0.75%. Regarding short-term risk, TGTX is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check ARWR's competition here
Arcellx, Inc. (NASDAQ: ACLX)
TGTX vs ACLX Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas ACLX's P/E ratio is -28.27. In terms of profitability, TGTX's ROE is +0.18%, compared to ACLX's ROE of -0.40%. Regarding short-term risk, TGTX is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check ACLX's competition here
CG Oncology Inc. (NASDAQ: CGON)
TGTX vs CGON Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, CGON has a market cap of 6.6B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while CGON trades at $74.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas CGON's P/E ratio is -27.66. In terms of profitability, TGTX's ROE is +0.18%, compared to CGON's ROE of -0.25%. Regarding short-term risk, TGTX is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check CGON's competition here
Belite Bio, Inc (NASDAQ: BLTE)
TGTX vs BLTE Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, BLTE has a market cap of 6.6B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while BLTE trades at $164.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas BLTE's P/E ratio is -87.89. In terms of profitability, TGTX's ROE is +0.18%, compared to BLTE's ROE of -0.17%. Regarding short-term risk, TGTX is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check BLTE's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
TGTX vs CAI Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, CAI has a market cap of 6.6B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while CAI trades at $23.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas CAI's P/E ratio is 64.74. In terms of profitability, TGTX's ROE is +0.18%, compared to CAI's ROE of +0.16%. Regarding short-term risk, TGTX is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check CAI's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
TGTX vs RETA Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas RETA's P/E ratio is -66.29. In terms of profitability, TGTX's ROE is +0.18%, compared to RETA's ROE of +0.47%. Regarding short-term risk, TGTX is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check RETA's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
TGTX vs IBRX Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, IBRX has a market cap of 6.4B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while IBRX trades at $6.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas IBRX's P/E ratio is -6.21. In terms of profitability, TGTX's ROE is +0.18%, compared to IBRX's ROE of +1.25%. Regarding short-term risk, TGTX is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check IBRX's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
TGTX vs CNTA Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas CNTA's P/E ratio is -22.63. In terms of profitability, TGTX's ROE is +0.18%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, TGTX is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check CNTA's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
TGTX vs LGND Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, LGND has a market cap of 6.2B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while LGND trades at $308.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas LGND's P/E ratio is 33.90. In terms of profitability, TGTX's ROE is +0.18%, compared to LGND's ROE of +0.05%. Regarding short-term risk, TGTX is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check LGND's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
TGTX vs MIRM Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, MIRM has a market cap of 6.1B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while MIRM trades at $93.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas MIRM's P/E ratio is -6.46. In terms of profitability, TGTX's ROE is +0.18%, compared to MIRM's ROE of -7.34%. Regarding short-term risk, TGTX is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check MIRM's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
TGTX vs TERN Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, TERN has a market cap of 6.1B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas TERN's P/E ratio is -51.41. In terms of profitability, TGTX's ROE is +0.18%, compared to TERN's ROE of -0.14%. Regarding short-term risk, TGTX is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check TERN's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
TGTX vs CDTX Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas CDTX's P/E ratio is -19.77. In terms of profitability, TGTX's ROE is +0.18%, compared to CDTX's ROE of -0.24%. Regarding short-term risk, TGTX is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
TGTX vs ABCM Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, TGTX's ROE is +0.18%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, TGTX is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
TGTX vs ISEE Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas ISEE's P/E ratio is -22.44. In terms of profitability, TGTX's ROE is +0.18%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, TGTX is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check ISEE's competition here
Erasca, Inc. (NASDAQ: ERAS)
TGTX vs ERAS Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, ERAS has a market cap of 5.5B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while ERAS trades at $15.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas ERAS's P/E ratio is -16.84. In terms of profitability, TGTX's ROE is +0.18%, compared to ERAS's ROE of -0.62%. Regarding short-term risk, TGTX is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check ERAS's competition here
Veradermics, Incorporated (NYSE: MANE)
TGTX vs MANE Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, MANE has a market cap of 5.5B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while MANE trades at $129.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas MANE's P/E ratio is -41.27. In terms of profitability, TGTX's ROE is +0.18%, compared to MANE's ROE of -0.20%. Regarding short-term risk, TGTX is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check MANE's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
TGTX vs PTCT Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, PTCT has a market cap of 5.3B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while PTCT trades at $63.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas PTCT's P/E ratio is -45.35. In terms of profitability, TGTX's ROE is +0.18%, compared to PTCT's ROE of +0.57%. Regarding short-term risk, TGTX is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check PTCT's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
TGTX vs SRRK Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, SRRK has a market cap of 5.3B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while SRRK trades at $43.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas SRRK's P/E ratio is -12.52. In terms of profitability, TGTX's ROE is +0.18%, compared to SRRK's ROE of -1.75%. Regarding short-term risk, TGTX is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check SRRK's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
TGTX vs APLS Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas APLS's P/E ratio is 38.35. In terms of profitability, TGTX's ROE is +0.18%, compared to APLS's ROE of +0.40%. Regarding short-term risk, TGTX is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check APLS's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
TGTX vs DNTH Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, DNTH has a market cap of 5.2B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while DNTH trades at $91.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas DNTH's P/E ratio is -22.12. In terms of profitability, TGTX's ROE is +0.18%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, TGTX is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check DNTH's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
TGTX vs COGT Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, COGT has a market cap of 5B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while COGT trades at $28.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas COGT's P/E ratio is -13.54. In terms of profitability, TGTX's ROE is +0.18%, compared to COGT's ROE of -0.71%. Regarding short-term risk, TGTX is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check COGT's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
TGTX vs EWTX Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, EWTX has a market cap of 4.9B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while EWTX trades at $45.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas EWTX's P/E ratio is -24.83. In terms of profitability, TGTX's ROE is +0.18%, compared to EWTX's ROE of +1.30%. Regarding short-term risk, TGTX is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check EWTX's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
TGTX vs TVTX Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, TVTX has a market cap of 4.9B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while TVTX trades at $50.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas TVTX's P/E ratio is -112.56. In terms of profitability, TGTX's ROE is +0.18%, compared to TVTX's ROE of -1.86%. Regarding short-term risk, TGTX is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check TVTX's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
TGTX vs IONS Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, IONS has a market cap of 4.8B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while IONS trades at $29.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas IONS's P/E ratio is -8.89. In terms of profitability, TGTX's ROE is +0.18%, compared to IONS's ROE of -1.20%. Regarding short-term risk, TGTX is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check IONS's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
TGTX vs ADPT Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, ADPT has a market cap of 4.7B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while ADPT trades at $29.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas ADPT's P/E ratio is -70.83. In terms of profitability, TGTX's ROE is +0.18%, compared to ADPT's ROE of -0.37%. Regarding short-term risk, TGTX is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check ADPT's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
TGTX vs FOLD Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas FOLD's P/E ratio is -161.00. In terms of profitability, TGTX's ROE is +0.18%, compared to FOLD's ROE of -0.02%. Regarding short-term risk, TGTX is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
TGTX vs AKRO Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas AKRO's P/E ratio is -14.57. In terms of profitability, TGTX's ROE is +0.18%, compared to AKRO's ROE of -0.15%. Regarding short-term risk, TGTX is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
TGTX vs ALPN Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas ALPN's P/E ratio is -101.52. In terms of profitability, TGTX's ROE is +0.18%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, TGTX is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check ALPN's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
TGTX vs DFTX Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, DFTX has a market cap of 4.4B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while DFTX trades at $32.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas DFTX's P/E ratio is N/A. In terms of profitability, TGTX's ROE is +0.18%, compared to DFTX's ROE of -0.54%. Regarding short-term risk, TGTX is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check DFTX's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
TGTX vs TNGX Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, TNGX has a market cap of 4.3B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while TNGX trades at $25.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas TNGX's P/E ratio is -30.72. In terms of profitability, TGTX's ROE is +0.18%, compared to TNGX's ROE of -0.30%. Regarding short-term risk, TGTX is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check TNGX's competition here
Opthea Limited (NASDAQ: OPT)
TGTX vs OPT Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas OPT's P/E ratio is -1.52. In terms of profitability, TGTX's ROE is +0.18%, compared to OPT's ROE of +1.18%. Regarding short-term risk, TGTX is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
TGTX vs PRTC Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas PRTC's P/E ratio is -3.78. In terms of profitability, TGTX's ROE is +0.18%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, TGTX is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check PRTC's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
TGTX vs MRTX Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas MRTX's P/E ratio is -4.82. In terms of profitability, TGTX's ROE is +0.18%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, TGTX is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check MRTX's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
TGTX vs CRSP Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, CRSP has a market cap of 4.1B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while CRSP trades at $42.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas CRSP's P/E ratio is -8.87. In terms of profitability, TGTX's ROE is +0.18%, compared to CRSP's ROE of -0.26%. Regarding short-term risk, TGTX is similarly volatile compared to CRSP. This indicates similar risk in terms of short-term price fluctuations for TGTX.Check CRSP's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
TGTX vs RLAY Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, RLAY has a market cap of 4B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while RLAY trades at $18.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas RLAY's P/E ratio is -11.52. In terms of profitability, TGTX's ROE is +0.18%, compared to RLAY's ROE of -0.40%. Regarding short-term risk, TGTX is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check RLAY's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
TGTX vs XENE Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, XENE has a market cap of 4B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while XENE trades at $40.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas XENE's P/E ratio is -8.61. In terms of profitability, TGTX's ROE is +0.18%, compared to XENE's ROE of -0.40%. Regarding short-term risk, TGTX is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check XENE's competition here
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS)
TGTX vs TARS Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, TARS has a market cap of 4B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while TARS trades at $80.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas TARS's P/E ratio is -73.65. In terms of profitability, TGTX's ROE is +0.18%, compared to TARS's ROE of -2.46%. Regarding short-term risk, TGTX is less volatile compared to TARS. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check TARS's competition here
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
TGTX vs AMLX Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, AMLX has a market cap of 3.9B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while AMLX trades at $30.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas AMLX's P/E ratio is -20.19. In terms of profitability, TGTX's ROE is +0.18%, compared to AMLX's ROE of -0.42%. Regarding short-term risk, TGTX is less volatile compared to AMLX. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check AMLX's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
TGTX vs CPRX Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas CPRX's P/E ratio is 17.49. In terms of profitability, TGTX's ROE is +0.18%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, TGTX is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check CPRX's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
TGTX vs ABCL Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, ABCL has a market cap of 3.8B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while ABCL trades at $11.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas ABCL's P/E ratio is -21.28. In terms of profitability, TGTX's ROE is +0.18%, compared to ABCL's ROE of -0.15%. Regarding short-term risk, TGTX is less volatile compared to ABCL. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check ABCL's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
TGTX vs RYZB Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas RYZB's P/E ratio is -57.86. In terms of profitability, TGTX's ROE is +0.18%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, TGTX is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
TGTX vs CBAY Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas CBAY's P/E ratio is -32.81. In terms of profitability, TGTX's ROE is +0.18%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, TGTX is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check CBAY's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
TGTX vs VKTX Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while VKTX trades at $29.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas VKTX's P/E ratio is -5.41. In terms of profitability, TGTX's ROE is +0.18%, compared to VKTX's ROE of -1.17%. Regarding short-term risk, TGTX is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check VKTX's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
TGTX vs ELVN Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, ELVN has a market cap of 3.6B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while ELVN trades at $48.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas ELVN's P/E ratio is -29.22. In terms of profitability, TGTX's ROE is +0.18%, compared to ELVN's ROE of -0.17%. Regarding short-term risk, TGTX is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check ELVN's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
TGTX vs IOVA Comparison November 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 9.8B. In comparison, IOVA has a market cap of 3.6B. Regarding current trading prices, TGTX is priced at $64.51 on the NASDAQ, while IOVA trades at $7.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 23.37, whereas IOVA's P/E ratio is -10.63. In terms of profitability, TGTX's ROE is +0.18%, compared to IOVA's ROE of -0.30%. Regarding short-term risk, TGTX is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check IOVA's competition here